| http://www.w3.org/ns/prov#value | - The offering is expected to close on May 16.PROLOR plans to use the net proceeds from this offering for general corporate purposes, which may include research and development expenses, including expenses related to clinical trials, capital expenditures, working capital, and general and administrative expenses.
|
